Back to Results

Navin K. Kapur, MD, FAHA, FACC, FSCAI Accepting New Patients

Programs + Specialties
Training + Education Georgetown University School of Medicine; Beth Israel Deaconess Medical Center; Johns Hopkins Hospital
Board Certifications Internal Medicine, Cardiovascular Disease, Interventional Cardiology, Advanced Heart Failure/Cardiac Transplant Medicine
NPI # 1902959554
Gender Male
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Tufts Medical Center
Proger Building, 6th Floor
800 Washington St.
Box 70
Boston, MA 02111
Phone #: 617-636-8252
Fax #: 617-636-5913

2016, Beals-Goodfellow Research Mentor Award – Tufts Medical Center
2013, Hildner Elite Reviewer Award – Catheterization & Cardiovascular Interv J (SCAI)
2012, Beals-Goodfellow Research Mentor Award – Tufts Medical Center
2012, Pfizer Clinical Therapeutics Innovation (CTI) – Finalist
2011, Northwestern University Early Cardiovascular Career Investigator Award – Finalist
2011, American Heart Association – BCVS Early Career Investigator Award – Finalist
BCVS Scientific Sessions
2011-2013, SCAI Emerging Interventional Leader-Mentor (ELM) Program Award
2009, Cardiology Fellows Outstanding Faculty Teaching Award – Tufts University School of Medicine
2007, American Heart Association – ATVB Young Investigator Merit Award
2006, American College of Cardiology Young Investigator Award – First Place; Molecular Cardiology Division
2005, American Heart Association Basic Cardiovascular Science New Investigator Award
2005, Jay N. Cohn New Investigator Basic Science Award – Second Place; Heart Failure Society of America
2005, Stanley L. Blumenthal Cardiovascular Research Award – First Place; Johns Hopkins University School of Medicine
2005, 11th Annual AstraZeneca / Jeremiah Stamler Young Investigator Award – First Place
2002, Harvard Medical School Excellence in Student Teaching Award
2001, James Tullis Resident Teaching Award, Harvard Medical School; Boston, MA

1. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V, Baker C, Aronovitz MJ, Karumanchi SA, Letarte M, Kass DA, Mendelsohn ME, Karas RH. Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure. Circulation. Accepted and in press 2012.

2. Kapur NK, Shenoy C, Yunis AA, Mohammad NN, Wilson S, Paruchuri V, Mackey EE, Qiao X, Shah A, Esposito M, Karas RH, Jaffe IZ. Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides. PLoS One. Accepted and in press 2012.

3. Heffernan KS, Eshan A, Parvardhan A, Kapur NK, Karas RH, Kuvin JT. Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach. Eur J Appl Physiol. 2011 Dec 3. Epub ahead of print.

4. Kapur NK, Kociol R. Rise of the Machines... and their Mechanics. Catheter Cardiovasc Interv. 2011 Nov 15;78(6):962-3.

5. Korabathina R, Heffernan KS, Paruchuri V, Patel AR, Mudd JO, Prutkin JM, Orr N, Weintraub A, Kimmelstiel CD, Kapur NK. The Pulmonary Artery Pulsatility Index Identifies Severe Right Ventricular Dysfunction in Acute Inferior Myocardial Infarction. Catheter Cardiovasc Interv. 2011 Sep 27.

6. Heffernan KS, Kuvin JT, Patel A, Karas RH, Kapur NK. Endothelial function and Soluble Endoglin in Smokers with Heart Failure. Clin Card 2011 Nov 28.

7. Kapur NK, Paruchuri V, Korabathina R, Esposito M, Shah A, Sech C, Kiernan M, Patel A, Orr N, Pham DT, Konstam M, DeNofrio D. Effects of a Percutaneous Mechanical Circulatory Support Device for Medically Refractory Right Ventricular Failure. J Heart Lung Transplant. 2011 Dec; 30(12):1360-7.

8. Kapur NK, Bian Ce, Lin E, Sperry JL, Deming CB, Hansen BS, Rade JJ. Inhibition of Transforming Growth Factor-beta Restores Endothelial Thromboresistance in Vein Grafts. J Vasc Surgery. 2011 Jul 29 [Epub ahead of print]

9. Kapur NK. Transforming Growth Factor-beta: Governing the Transition from Inflammation to Fibrosis in Heart Failure with Preserved Left Ventricular Function. Circulation: Heart Failure 2011 Jan 1;4(1):5-7.

10. Kapur NK, Yunis AA, Parpos P, Heffernan KH, Aronovitz MJ, Baker C, Wilson S, Shah A, Epsoito M, Kimmelstiel CD, Weintraub A, Karas RH, Mendelsohn ME. Soluble fms-like Tyrosine Kinase (sFLT1): A Highly Sensitive Biomarker of Acute ST-segment Elevation Myocardial Infarction (STEMI). Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):443-50.

View all of Dr. Kapur's publications on PubMed.

Dr. Kapur is a dual, board-certified Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist. He is Director of the Acute Circulatory Support Program and Associate Director of the Cardiac Catheterization Laboratory at Tufts Medical Center. His clinical expertise focuses on invasive hemodynamics, mechanical circulatory support, and interventional therapies for patients with advanced heart failure. He serves on several national committees involved with the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, and the Society for Cardiac Angiography and Interventions.

As Director of the Interventional Research Laboratories at Tufts Medical , Dr. Kapur’s translational research focuses on large animal models of acute and chronic heart failure, circulatory support device development, and cardioprotective mechanisms in the setting of acute myocardial infarction. His recent work has focused on the hypothesis that mechanically unloading the heart and delaying coronary reperfusion limits infarct size. This concept known as the 'mechanical conditioning hypothesis' has the potential to alter the paradigm of acute heart attack therapy and reduce the burden of ischemic heart failure.

As Director of the Cardiac Biology Research Center within the Molecular Cardiology Research Institute at Tufts Medical Center, Dr. Kapur’s basic science laboratory focuses on molecular mechanisms governing maladaptive cardiac remodeling in heart failure. His particular expertise involves signaling via the transforming growth factor beta (TGFb) system. Over the past 6 years, the laboratory has published several critical papers focused on a TGFb co-receptor known as endoglin and was the first to establish that reduced endoglin activity improves survival and limits maladaptive cardiac remodeling in heart failure. More recently, the laboratory has demonstrated that targeting endoglin using an antibody-mediated approach not only limits the development of cardiac fibrosis, but can reverse established cardiac fibrosis in preclinical models of heart failure. Dr. Kapur is the recipient of grant funding from the National Institutes of Health, American Heart Association, and several industry sponsors.

American Heart Association
American College of Cardiology
Heart Failure Society of America
Society of Coronary Angiography and Interventions

Boston Magazine Top Doctors 2023

2023 “Top Doctors” at Tufts Medical Center

See our Top Doctors
Boston Magazine 2022 Top Doctors

2022 “Top Doctors” at Tufts Medical Center

See our Top Doctors
News graphic

New approach to treating heart attack

Watch the news clip
Don Swarce is a Tufts MC patient for life

Don's story: Enjoying life again

Learn why Don is a Tufts MC patient for life
Navin Kapur, MD works with a group of multidisciplinary individuals to raise awareness and improve cardiogenic shock treatments

Navin Kapur, MD discusses cardiogenic shock treatment strategies that a work group developed with the goal of improving outcomes.

Learn more about cardiogenic shock treatment strategies
Christine Alber is a patient at Tufts Medical Center in Boston.

Christine Alber's story: A team approach saves the day.

Read Christine's story
Guillermo Roman and his cardiologist, Dr. Navin Kapur at Tufts Medical Center - 5 years after his VAD implant at the Boston hospital.

We were prepared for Guillermo's heart attack

Read Guillermo's story
Wendy after a heart pump was placed

First ever expandable heart pump

Learn how this pump helps patients not miss a beat

Understanding the Translational Value of PV Loops from Mouse to Man
In this webinar, Dr. Kapur discusses how PV loop data can translate over from mouse to man and provide a confident approach to evaluating drug studies, device validation and treatments outcomes.
View on SlideShare >